Vireo Growth
Cannabis operator with dispensaries and cultivation across multiple US states.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
The model outputs a Neutral rating for Vireo Growth, scoring 59/100 at conviction 2 of 5. Weights are locked at 35 percent fundamentals, 25 percent regulatory, 25 percent market, and 15 percent editorial, and each pillar is broken out for direct review. The fundamentals pillar contributes the largest share at 88, pulling the composite into the middle of the band. Opposite that, editorial prints only 30, and is what keeps the rating anchored where it is.
Pillar-level, the record reads as reported revenue growth of 333.5 percent year over year, an operating margin of 16.7 percent, a filing cadence of 1 regulator events in the trailing 90 days. Each of those data points tethers the Neutral conclusion to observable evidence. Inputs are limited to primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, plus a density read from CIN newsroom coverage. The rating enables direct comparison across the 336 tickers in the CIN coverage universe on a consistent, deterministic basis, and refreshes on a scheduled cadence tied to the primary-source ingest cycle.
The clearest catalyst is the next quarterly print. Fundamentals contribute 88 of the composite, and either an acceleration in top-line growth or a stabilization of the operating margin would move the score higher; a deterioration on either would compress it.
- IR email
- investor@vireogrowth.com
- IR page
- Investor relations
- Headquarters
- 207 SOUTH 9TH STREET, MINNEAPOLIS, MN, 55402
- Phone
- 604-617-5421
- CEO
- John Mazarakis
- CFO
- Tyson Macdonald
- SEC CIK
- 1771706
- Website
- Company website
- Market cap
- $490.7M
- Enterprise value
- $769.4M
- Price to book
- 1.67
- Price to sales
- 1.40
- EV / EBITDA
- 40.49
- Revenue (TTM)
- $350.5M
- Gross profit (TTM)
- $174.0M
- EBITDA
- $45.2M
- Operating margin
- 16.7%
- Profit margin
- -23.4%
- Rev growth YoY
- 333.5%
- Return on equity
- -47.5%
- Return on assets
- 2.6%
- EPS (TTM)
- $-2.70
- EPS est. current year
- $0.20
- Wall St. target price
- $45.00
- Shares outstanding
- 48.5M
- Insider ownership
- 33.2%
- Institutional ownership
- 7.8%
- Beta
- 0.07
- Full-time employees
- 520
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Vireo Growth (VREOF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Vireo Growth (VREOF), a cannabis-sector equity listed on OTCMKTS in the US MSO category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (3 bullish signals, 1 bearish signal.)
Cannabis operator with dispensaries and cultivation across multiple US states.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for VREOF are maintained by Cannabis Investor News and refreshed throughout the trading day.